focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amphion Innovations plc (LSE: ''AMP'') Announces First Annual Science & Business Symposium ''Building Market Value from the World of Genetics''

14 May 2007 16:25

As a result of the mapping of the human genome, genetic researchis impacting scientific discovery in profound ways. This includeseverything from understanding the underlying causes of diseases to theregulation of cellular functions, faster disease detection and thecreation of new drugs. To speak about these topics, CEOs fromMyconostica, Ltd., Motif BioSciences, Inc. and WellGen, Inc. willshare exciting new research trends from the world of genetics. £ The Genetics Symposium is sponsored by Amphion Innovations, plc,(LSE: AMP) a developer of companies planning to commercializeintellectual property in life sciences and technology. Amphion'smanagement team has created more than US $14B in aggregate marketcapitalization and has played an instrumental role in co-foundingcompanies, such as Celgene (NASD: CELG) and Medisense (NYSE: ABT). \* TWHAT:Amphion Innovations plc, a developer of life science and technologybusinesses, will introduce the work of its Partner Companies andshowcase its proven model for commercializing highly disruptive IP. WHO:Mr. Richard Morgan, CEO Amphion Innovations plc will describeAmphion's approach to building $100 million plus businesses in the UKand US markets Dr. David Denning, CEO Myconostica, Ltd. will speak on the use ofmolecular genetics for rapid diagnosis of deadly infections Mr. Zaki Hosny, CEO Motif BioSciences, Inc. will speak on howpopulation genetics is being used to isolate certain diseasemutations, such as diabetes and autism Dr. Kathleen Mullinix, CEO WellGen, Inc. will discuss developingfunctional foods and screening for natural ingredients that affectgene expression WHERE:American Conference Centers, 780 Third Avenue (48/49 St.) New YorkCity WHEN:May 15th, from 4:30-7:00 PM. Refreshments will be served. To confirm your presence at the symposium or to receive additionalinformation, please contact: Nicole Allen/Josh Berkman(646) 747-7161 or (917) 528-1066/(646) 747-7158 or 718-490-6905nallen@kwitco.com/jberkman@kwitco.com\* T Copyright Business Wire 2007
Date   Source Headline
8th Jun 20067:01 amRNSAppointment
6th Jun 20067:01 amRNSRe Agreement
5th Jun 20063:16 pmRNSThe Shafallah Center
2nd Jun 20065:01 pmRNSDr David Evans
1st Jun 20067:00 amRNSAnnual Report and Accounts
23rd May 20067:00 amRNSDirector/PDMR Shareholding
22nd May 20061:41 pmRNSDirector/PDMR Shareholding
19th May 20065:12 pmRNSDirector Share Transaction
15th Mar 20069:25 amRNSCompletion of a Financing
8th Mar 20067:04 amRNSFinal Results
2nd Mar 20069:12 amRNSMotif BioSciences
27th Feb 20064:56 pmRNSNotice of Results
23rd Feb 20067:02 amRNSRe: WellGen Financing
3rd Jan 20067:01 amRNSAdditional Investments
5th Dec 200512:48 pmRNSDirector Shareholding
10th Oct 20057:00 amRNSAcquires a stake
21st Sep 20057:00 amRNSStake in Spin-Out Company
30th Aug 20057:00 amRNSAmphion Invests in WellGen
25th Aug 20054:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.